Moderna reports Canadian authorization of flu and combined flu–COVID mRNA vaccines
Company / institutional announcement · Moderna (ACCESS Newswire via Newscom)
Source published:
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.
Why it may matter
Potential business implication: additional respiratory-vaccine authorizations may expand mRNA manufacturing demand; authorization alone does not establish launch timing or commercial uptake.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections